These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

155 related articles for article (PubMed ID: 25531162)

  • 1. Design of a phase 2 clinical trial of an ASK1 inhibitor, GS-4997, in patients with diabetic kidney disease.
    Lin JH; Zhang JJ; Lin SL; Chertow GM
    Nephron; 2015; 129(1):29-33. PubMed ID: 25531162
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Estimated glomerular filtration rate progression in UK primary care patients with type 2 diabetes and diabetic kidney disease: a retrospective cohort study.
    Cid Ruzafa J; Paczkowski R; Boye KS; Di Tanna GL; Sheetz MJ; Donaldson R; Breyer MD; Neasham D; Voelker JR
    Int J Clin Pract; 2015 Aug; 69(8):871-82. PubMed ID: 26011029
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effect of addition of silymarin to renin-angiotensin system inhibitors on proteinuria in type 2 diabetic patients with overt nephropathy: a randomized, double-blind, placebo-controlled trial.
    Fallahzadeh MK; Dormanesh B; Sagheb MM; Roozbeh J; Vessal G; Pakfetrat M; Daneshbod Y; Kamali-Sarvestani E; Lankarani KB
    Am J Kidney Dis; 2012 Dec; 60(6):896-903. PubMed ID: 22770926
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Residual proteinuria and eGFR predict progression of renal impairment within 2 years in type 2 diabetic patients with nephropathy who are receiving optimal treatment with angiotensin receptor blockers.
    Ivory SE; Packham DK; Reutens AT; Wolfe R; Rohde RD; Lewis J; Atkins RC;
    Nephrology (Carlton); 2013 Jul; 18(7):516-24. PubMed ID: 23506627
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Spironolactone in type 2 diabetic nephropathy: Effects on proteinuria, blood pressure and renal function.
    van den Meiracker AH; Baggen RG; Pauli S; Lindemans A; Vulto AG; Poldermans D; Boomsma F
    J Hypertens; 2006 Nov; 24(11):2285-92. PubMed ID: 17053552
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Chinese herbal medicine Tangshen Formula treatment of patients with type 2 diabetic kidney disease with macroalbuminuria: study protocol for a randomized controlled trial.
    Yan M; Wen Y; Yang L; Wu X; Lu X; Zhang B; Huang W; Li P
    Trials; 2016 May; 17(1):259. PubMed ID: 27216240
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effects of Selonsertib in Patients with Diabetic Kidney Disease.
    Chertow GM; Pergola PE; Chen F; Kirby BJ; Sundy JS; Patel UD;
    J Am Soc Nephrol; 2019 Oct; 30(10):1980-1990. PubMed ID: 31506292
    [TBL] [Abstract][Full Text] [Related]  

  • 8. ASK1 contributes to fibrosis and dysfunction in models of kidney disease.
    Liles JT; Corkey BK; Notte GT; Budas GR; Lansdon EB; Hinojosa-Kirschenbaum F; Badal SS; Lee M; Schultz BE; Wise S; Pendem S; Graupe M; Castonguay L; Koch KA; Wong MH; Papalia GA; French DM; Sullivan T; Huntzicker EG; Ma FY; Nikolic-Paterson DJ; Altuhaifi T; Yang H; Fogo AB; Breckenridge DG
    J Clin Invest; 2018 Oct; 128(10):4485-4500. PubMed ID: 30024858
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Efficacy and safety of tangshen formula on patients with type 2 diabetic kidney disease: a multicenter double-blinded randomized placebo-controlled trial.
    Li P; Chen Y; Liu J; Hong J; Deng Y; Yang F; Jin X; Gao J; Li J; Fang H; Liu G; Shi L; Du J; Li Y; Yan M; Wen Y; Yang W
    PLoS One; 2015; 10(5):e0126027. PubMed ID: 25938778
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Spironolactone diminishes urinary albumin excretion in patients with type 1 diabetes and microalbuminuria: a randomized placebo-controlled crossover study.
    Nielsen SE; Persson F; Frandsen E; Sugaya T; Hess G; Zdunek D; Shjoedt KJ; Parving HH; Rossing P
    Diabet Med; 2012 Aug; 29(8):e184-90. PubMed ID: 22268920
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Chinese herbal medicine Shenzhuo Formula treatment in patients with macroalbuminuria secondary to diabetic kidney disease: study protocol for a randomized controlled trial.
    Zhao XM; Zhang Y; He XH; Chen HD; Wang ZF; Guo J; Wang XM; Gao ZZ; Wang JP; Liu W; Zhao LH; Tong XL
    Trials; 2018 Mar; 19(1):200. PubMed ID: 29587863
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effects of traditional Chinese herbal medicine in patients with diabetic kidney disease: study protocol for a randomized controlled trial.
    Wang M; Wang Z; Zhou J; Sun W; Wang Y; Han M; Yang H; Liu WJ; Wang Y
    Trials; 2018 Jul; 19(1):389. PubMed ID: 30016983
    [TBL] [Abstract][Full Text] [Related]  

  • 13. JAK1/JAK2 inhibition by baricitinib in diabetic kidney disease: results from a Phase 2 randomized controlled clinical trial.
    Tuttle KR; Brosius FC; Adler SG; Kretzler M; Mehta RL; Tumlin JA; Tanaka Y; Haneda M; Liu J; Silk ME; Cardillo TE; Duffin KL; Haas JV; Macias WL; Nunes FP; Janes JM
    Nephrol Dial Transplant; 2018 Nov; 33(11):1950-1959. PubMed ID: 29481660
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Aliskiren Trial in Type 2 Diabetes Using Cardio-Renal Endpoints (ALTITUDE): rationale and study design.
    Parving HH; Brenner BM; McMurray JJ; de Zeeuw D; Haffner SM; Solomon SD; Chaturvedi N; Ghadanfar M; Weissbach N; Xiang Z; Armbrecht J; Pfeffer MA
    Nephrol Dial Transplant; 2009 May; 24(5):1663-71. PubMed ID: 19145003
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Combination of half doses of angiotensin type 1 receptor antagonist and angiotensin-converting enzyme inhibitor in diabetic nephropathy.
    Fujisawa T; Ikegami H; Ono M; Nishino M; Noso S; Kawabata Y; Ogihara T
    Am J Hypertens; 2005 Jan; 18(1):13-7. PubMed ID: 15691611
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Angiotensin-receptor blockade versus converting-enzyme inhibition in type 2 diabetes and nephropathy.
    Barnett AH; Bain SC; Bouter P; Karlberg B; Madsbad S; Jervell J; Mustonen J;
    N Engl J Med; 2004 Nov; 351(19):1952-61. PubMed ID: 15516696
    [TBL] [Abstract][Full Text] [Related]  

  • 17. To RAS or not to RAS? The evidence for and cautions with renin-angiotensin system inhibition in patients with diabetic kidney disease.
    St Peter WL; Odum LE; Whaley-Connell AT
    Pharmacotherapy; 2013 May; 33(5):496-514. PubMed ID: 23576066
    [TBL] [Abstract][Full Text] [Related]  

  • 18. ASK1 Inhibitor Halts Progression of Diabetic Nephropathy in Nos3-Deficient Mice.
    Tesch GH; Ma FY; Han Y; Liles JT; Breckenridge DG; Nikolic-Paterson DJ
    Diabetes; 2015 Nov; 64(11):3903-13. PubMed ID: 26180085
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Resveratrol reduces albuminuria in diabetic nephropathy: A randomized double-blind placebo-controlled clinical trial.
    Sattarinezhad A; Roozbeh J; Shirazi Yeganeh B; Omrani GR; Shams M
    Diabetes Metab; 2019 Jan; 45(1):53-59. PubMed ID: 29983230
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effect of low-dose dual blockade of renin-angiotensin system on urinary TGF-beta in type 2 diabetic patients with advanced kidney disease.
    Song JH; Cha SH; Lee HJ; Lee SW; Park GH; Lee SW; Kim MJ
    Nephrol Dial Transplant; 2006 Mar; 21(3):683-9. PubMed ID: 16330466
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.